Literature DB >> 24850557

Managing advanced unilateral pseudoexfoliative glaucoma.

André Marques1.   

Abstract

The only proven therapy for glaucoma is intraocular pressure (IOP) reduction, which can be accomplished by different means. Each should be properly discussed with patients in order to best preserve visual function and quality of life. We report a case of unilateral pseudoexfoliative glaucoma, treated for years with triple topical IOP-lowering drugs. The patient presented with advanced optic neuropathy and important ocular side effects secondary to the treatment. Having discussed his options and prognosis, laser trabeculoplasty was performed while maintaining the remaining therapy considering the advanced stage of glaucoma. His IOP was effectively reduced and no progression was noted after 1-year follow-up. Although medical therapy is the mainstream in glaucoma management, its side effects should not be ignored, especially in unilateral cases. Surgery might have been a better solution, but we chose to perform laser trabeculoplasty, an effective and safer alternative, considering the unlikely but serious risk of the "wipe-out phenomenon" in this case. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850557      PMCID: PMC4039938          DOI: 10.1136/bcr-2014-204011

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Risk of sudden visual loss following filtration surgery in end-stage glaucoma.

Authors:  Fotis Topouzis; Paris Tranos; Archimidis Koskosas; Theofanis Pappas; Eleftherios Anastasopoulos; Stavros Dimitrakos; M Roy Wilson
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

2.  The presentation and prognosis of glaucoma in pseudoexfoliation of the lens capsule.

Authors:  A M Brooks; W E Gillies
Journal:  Ophthalmology       Date:  1988-02       Impact factor: 12.079

3.  Toxic-inflammatory effects of prostoglandin analogs on the ocular surface.

Authors:  Soner Demirel; Selim Doganay; Iclal Gurses; Mustafa Iraz
Journal:  Ocul Immunol Inflamm       Date:  2013       Impact factor: 3.070

4.  Preservative exposure and surgical outcomes in glaucoma patients: The PESO study.

Authors:  Corey Boimer; Catherine M Birt
Journal:  J Glaucoma       Date:  2013-12       Impact factor: 2.503

5.  Long-term follow-up of pseudoexfoliation and the development of elevated intraocular pressure.

Authors:  J C Henry; T Krupin; M Schmitt; J Lauffer; E Miller; M Q Ewing; H G Scheie
Journal:  Ophthalmology       Date:  1987-05       Impact factor: 12.079

6.  Evaluation of ocular surface disease in patients with glaucoma.

Authors:  Priya M Mathews; Pradeep Y Ramulu; David S Friedman; Canan A Utine; Esen K Akpek
Journal:  Ophthalmology       Date:  2013-05-25       Impact factor: 12.079

Review 7.  [Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy].

Authors:  A Yu; U Welge-Lüßen
Journal:  Klin Monbl Augenheilkd       Date:  2013-01-20       Impact factor: 0.700

8.  Iatrogenic glaucoma therapy failure: the adverse effects of topical antiglaucoma medication treatment outcome.

Authors:  Sophia K Mirza; Eve J Higginbotham
Journal:  Expert Rev Clin Pharmacol       Date:  2009-01       Impact factor: 5.045

9.  Severe loss of central vision in patients with advanced glaucoma undergoing trabeculectomy.

Authors:  Simon K Law; Anne M Nguyen; Anne L Coleman; Joseph Caprioli
Journal:  Arch Ophthalmol       Date:  2007-08
  9 in total
  2 in total

1.  Risk assessment of sudden visual loss following non-penetrating deep sclerectomy in severe and end-stage glaucoma.

Authors:  Igor Leleu; Benjamin Penaud; Esther Blumen-Ohana; Thibault Rodallec; Raphaël Adam; Olivier Laplace; Jad Akesbi; Jean-Philippe Nordmann
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

2.  Central 10-degree visual field change following non-penetrating deep sclerectomy in severe and end-stage glaucoma: preliminary results.

Authors:  Igor Leleu; Benjamin Penaud; Esther Blumen-Ohana; Thibault Rodallec; Raphaël Adam; Olivier Laplace; Jad Akesbi; Jean-Philippe Nordmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-03       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.